Arena Pharmaceuticals (ARNA) has an average broker rating of 2.5, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 considers that the stock is a Sell.
Arena Pharmaceuticals (ARNA) : The highest short term price target forecast on Arena Pharmaceuticals (ARNA) is $4 and the lowest target price is $2. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $3 with a standard deviation of $1.32.
Arena Pharmaceuticals (NASDAQ:ARNA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.60 and $1.56 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.61, notching a gain of 0.63% for the day. The total traded volume was 959,777 . The stock had closed at $1.60 on the previous day.
The company shares have dropped -61.81% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $5.12 and the one year low was seen on Jan 11, 2016. The 50-Day Moving Average price is $1.79 and the 200 Day Moving Average price is recorded at $1.71.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.